348 results on '"Shah, Mithun Vinod"'
Search Results
102. MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia
103. Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients
104. 327 - Outcome of Patients with Myelodysplastic Syndrome and a Monosomal Karyotype Following Allogeneic Stem Cell Transplant: Single Institution Experience
105. 475 - Incidence and Mortality Outcomes in Allogeneic Transplant-Associated Thrombotic Microangiopathy
106. 464 - Transplant Outcomes for Patients with Secondary Acute Myeloid Leukemia (AML) Arising From Myeloproliferative Neoplasms (MPN)
107. 341 - Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs
108. 325 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience
109. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
110. Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.
111. Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.
112. The Prognostic Impact of Minimal Residual Disease on Risk of Progression and Progression Free Survival in Acute Myeloid Leukemia
113. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients
114. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia
115. Association of hemophagocytic lymphohistiocytosis (HLH) with poor outcomes in adults with NK- and T-cell lymphoma (NKTCL).
116. Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience
117. EBV-positive peripheral T-cell lymphoma with extensive hemophagocytosis
118. 412 - Real Time PCR Detects Relapse of JAK2 V617F Myelofibrosis Earlier Than Pyrosequencing after Allogeneic Transplantation
119. 21 - Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients
120. Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact.
121. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
122. Never Say Die: Survival Signaling in Large Granular Lymphocyte Leukemia
123. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders
124. The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.
125. Network model of survival signaling in large granular lymphocyte leukemia.
126. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival
127. Clonal heterogeneity in <italic>STAG2</italic>m myeloid neoplasms: the Mayo Clinic experience.
128. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
129. Autoimmune manifestations in STAG2-mutated myeloid neoplasms.
130. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
131. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms
132. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
133. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
134. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
135. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.
136. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.
137. Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms.
138. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.
139. Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.
140. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.
141. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy.
142. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
143. The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant.
144. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
145. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
146. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
147. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
148. Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
149. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia.
150. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.